Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

Phase 3 ◽

Full Dose ◽

Re: Side Effects of bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-Risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-Third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

10.1016/j.juro.2014.09.034 ◽

2014 ◽

Vol 192 (6) ◽

pp. 1641-1641

Author(s):

David P. Wood

Keyword(s):

Side Effects ◽

High Risk ◽

Papillary Carcinoma ◽

Phase 3 ◽

Full Dose ◽

1694 SIDE EFFECTS OF BCG IN THE TREATMENT OF INTERMEDIATE AND HIGH RISK TA T1 PAPILLARY CARCINOMA OF THE BLADDER: RESULTS FROM EORTC GU CANCERS GROUP RANDOMIZED STUDY 30962 COMPARING 1/3 DOSE VS FULL DOSE DURING 1 OR 3 YEARS

10.1016/j.juro.2013.02.3004 ◽

2013 ◽

Vol 189 (4S) ◽

Author(s):

Maurizio Brausi ◽

Jorg Oddens ◽

Richard Sylvester ◽

Aldo Bono ◽

Paolo Gontero ◽

...

Keyword(s):

Side Effects ◽

High Risk ◽

Papillary Carcinoma ◽

Randomized Study ◽

Full Dose ◽

708 Side effects of BCG in the treatment of intermediate and high risk Ta T1 papillary carcinoma of the bladder: Results from EORTC GU Cancers Group randomized study 30962 comparing 1/3 dose vs full dose during 1 or 3 years

European Urology Supplements ◽

10.1016/s1569-9056(13)61190-2 ◽

2013 ◽

Vol 12 (1) ◽

pp. e708

Author(s):

M. Brausi ◽

J. Oddens ◽

R. Sylvester ◽

S. Colette ◽

P. Gontero ◽

...

Keyword(s):

Side Effects ◽

High Risk ◽

Papillary Carcinoma ◽

Randomized Study ◽

Full Dose ◽

Re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. Eur Urol 2010;57:766–73

European Urology ◽

10.1016/j.eururo.2010.02.037 ◽

2010 ◽

Vol 57 (6) ◽

pp. e57

Author(s):

Tommaso Cai ◽

Lorenzo Giuseppe Luciani ◽

Gianni Malossini

Keyword(s):

High Risk ◽

Urothelial Carcinoma ◽

Phase 3 ◽

Term Efficacy ◽

Carcinoma Of The Bladder ◽

Intravesical Instillations

PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE Ta T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-GUERIN. RESULTS OF EORTC GU GROUP STUDY 30911

10.1016/s0022-5347(08)61718-8 ◽

2008 ◽

Vol 179 (4S) ◽

pp. 586-586

Author(s):

Richard Sylvester ◽

Willem Oosterlinck ◽

Maurizio Brausi ◽

Wim J Kirkels ◽

Fernando Calais Da Silva ◽

...

Keyword(s):

Prognostic Factors ◽

High Risk ◽

Papillary Carcinoma ◽

Faculty Opinions recommendation of Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964808.793498086 ◽

2014 ◽

Author(s):

Alexander Bachmann ◽

Jan Ebbing

Keyword(s):

High Risk ◽

Urinary Bladder ◽

Papillary Carcinoma ◽

Randomized Study ◽

Full Dose

Faculty Opinions recommendation of Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964808.793466279 ◽

2012 ◽

Author(s):

Mark Gonzalgo

Keyword(s):

High Risk ◽

Urinary Bladder ◽

Papillary Carcinoma ◽

Randomized Study ◽

Full Dose

PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE TA T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-GUERIN. RESULTS OF EORTC GU GROUP STUDY 30911

European Urology Supplements ◽

10.1016/s1569-9056(08)60426-1 ◽

2008 ◽

Vol 7 (3) ◽

pp. 178

Author(s):

R.J. Sylvester ◽

W. Oosterlinck ◽

M.A. Brausi ◽

W.J. Kirkels ◽

F. Calais Da Silva ◽

...

Keyword(s):

Prognostic Factors ◽

High Risk ◽

Papillary Carcinoma ◽

INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIAL

10.1016/s0022-5347(05)65966-6 ◽

2001 ◽

Vol 166 (2) ◽

pp. 476-481 ◽

Cited By ~ 93

Author(s):

ADRIAN P.M. VAN DER MEIJDEN ◽

MAURIZIO BRAUSI ◽

VICTOR ZAMBON ◽

WIM KIRKELS ◽

CHRISTINE DE BALINCOURT ◽

...

Keyword(s):

High Risk ◽

Papillary Carcinoma ◽

Intravesical Instillation ◽

Phase Iii ◽

European Organization ◽

Phase Iii Trial ◽

Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

European Urology ◽

10.1016/j.eururo.2009.12.024 ◽

2010 ◽

Vol 57 (5) ◽

pp. 766-773 ◽

Cited By ~ 225

Author(s):

Richard J. Sylvester ◽

Maurizio A. Brausi ◽

Wim J. Kirkels ◽

Wolfgang Hoeltl ◽

Fernando Calais Da Silva ◽

...

Keyword(s):

High Risk ◽

Urothelial Carcinoma ◽

Phase 3 ◽

Term Efficacy ◽

Carcinoma Of The Bladder ◽

Intravesical Instillations